Cargando…

Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions

OBJECTIVE: The immune response to invasive carcinoma has been the focus of published work, but little is known about the adaptive immune response to bronchial premalignant lesions (PMLs), precursors of lung squamous cell carcinoma. This study was designed to characterize the T cell receptor (TCR) re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maoz, Asaf, Merenstein, Carter, Koga, Yusuke, Potter, Austin, Gower, Adam C, Liu, Gang, Zhang, Sherry, Liu, Hanqiao, Stevenson, Christopher, Spira, Avrum, Reid, Mary E, Campbell, Joshua D, Mazzilli, Sarah A, Lenburg, Marc E, Beane, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477334/ https://www.ncbi.nlm.nih.gov/pubmed/34580161 http://dx.doi.org/10.1136/jitc-2021-002647

Ejemplares similares

Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions
por: Beane, Jennifer E., et al.
Publicado: (2019)

Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression
por: Ning, Boting, et al.
Publicado: (2023)

Discovering biological connections between experimental conditions based on common patterns of differential gene expression
por: Gower, Adam C, et al.
Publicado: (2011)

2356: openSESAME: a “search engine” for discovering drug-disease connections by leveraging publicly available high-throughput experimental data
por: Gower, Adam C., et al.
Publicado: (2018)

Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression
por: Beane, Jennifer, et al.
Publicado: (2007)

Smoking Modulates Different Secretory Subpopulations Expressing SARS-CoV-2 Entry Genes in the Nasal and Bronchial Airways
por: Xu, Ke, et al.
Publicado: (2021)

Comparison of Nasal Epithelial Smoking-Induced Gene Expression on Affymetrix Exon 1.0 and Gene 1.0 ST Arrays
por: Zhang, Xiaoling, et al.
Publicado: (2013)

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies
por: Cham, Jason, et al.
Publicado: (2020)

Smoking modulates different secretory subpopulations expressing SARS-CoV-2 entry genes in the nasal and bronchial airways
por: Xu, Ke, et al.
Publicado: (2022)

Bronchial gene expression alterations associated with radiological bronchiectasis
por: Xu, Ke, et al.
Publicado: (2023)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
por: Philippon, Camille, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis
por: Xing, Xiaofang, et al.
Publicado: (2022)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

CX-072 (pacmilimab), a Probody(®) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
por: Naing, Aung, et al.
Publicado: (2021)

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma
por: Mohsen, Mona O, et al.
Publicado: (2022)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Reid, Pankti, et al.
Publicado: (2021)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

SIEGE: Smoking Induced Epithelial Gene Expression Database
por: Shah, Vishal, et al.
Publicado: (2005)

A very long-acting IL-15: implications for the immunotherapy of cancer
por: Hangasky, John A, et al.
Publicado: (2022)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
por: McNeel, Douglas G, et al.
Publicado: (2022)

Clinical Study of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers
por: Garland, Linda L., et al.
Publicado: (2022)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
por: Conlon, Kevin, et al.
Publicado: (2021)

Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy
por: Whitney, Duncan H, et al.
Publicado: (2015)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-17. CAR T CELLS TARGETING THE INTEGRIN ALPHA(V)BETA(3) EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND GLIOBLASTOMA (GBM)
por: Cobb, Dustin, et al.
Publicado: (2020)

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
por: Zhang, Yixiao, et al.
Publicado: (2020)

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
por: Alessi, Joao V, et al.
Publicado: (2020)

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
por: Lu, Chunwan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2bfemgu9l7d36b9legil14e9p